Small Molecule Inhibitors Targeting p300/HIF-1α Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors of protein-protein interactions, particularly the p300/HIF-1α interaction, face challenges such as low specificity and potency, with inhibitory concentrations often in the millimolar range, limiting their effectiveness in targeting hypoxia-induced transcription in tumors and other conditions.
Innovation Solution
Development of small molecule inhibitors with specific chemical structures, such as those according to Formula I and Formula II, that selectively inhibit the p300/HIF-1α interaction, including pharmaceutical compositions and methods for their synthesis and use, which are designed to effectively target and disrupt the binding between p300 and HIF-1α, thereby regulating hypoxia-responsive gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target the p300/HIF-1α interaction, then the ability to inhibit hypoxia-induced transcription is improved, but the potency and specificity are insufficient with inhibitory concentrations in the millimolar range
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of small molecule inhibitors to achieve lower inhibitory concentrations. The compounds described in Formula I and Formula II represent specific structural parameters that have been optimized to improve potency, transitioning from millimolar to lower concentration ranges while maintaining or enhancing inhibitory effectiveness against the p300/HIF-1α interaction.
2Reliability
If small molecule inhibitors are used to target the p300/HIF-1α interaction, then the ability to inhibit hypoxia-induced transcription is improved, but the specificity is insufficient
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that target particular regions of the p300/HIF-1α interaction interface. The compounds in Formula I and Formula II contain specific functional groups and structural elements (such as the R1, R2, R3 substituents and ring structures) that are optimized to bind selectively to specific domains, thereby improving specificity while maintaining inhibitory effectiveness.
Data Source
AI summary
Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 α subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.